Comprehensive medication guide to Lo Zumandimine 28 Day including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0 copay for most patients on ACA-compliant insurance plans (contraceptive mandate); Tier 1–2 on most commercial formularies. Patients on grandfathered plans or high-deductible plans may pay $15–$30 copay per cycle.
Estimated Cash Pricing
Retail price averages $156 per 28-tablet pack; as low as $30.91 with a GoodRx coupon for Lo Zumandimine, or as low as $6.20 for generic drospirenone/ethinyl estradiol with a SingleCare discount card for a 30-day supply.
Medfinder Findability Score
80/100
Summarize with AI
On this page
Lo Zumandimine 28 Day is a combination oral contraceptive (birth control pill) manufactured by Aurobindo Pharma Limited. It contains two synthetic hormones: drospirenone 3 mg (a progestin) and ethinyl estradiol 0.02 mg (an estrogen). Lo Zumandimine is an AB-rated generic equivalent of Yaz — one of the most prescribed birth control pills in the United States.
Each 28-tablet blister pack contains 24 active (light pink) hormone tablets and 4 inert (green) reminder tablets, following the 24/4 regimen. This regimen was specifically designed to minimize hormonal fluctuations — which is why it is FDA-approved not only for contraception, but also for premenstrual dysphoric disorder (PMDD) and moderate acne in women 14 years and older.
Lo Zumandimine is not a controlled substance and does not require any special DEA authorization or REMS program. It can be prescribed by OB-GYNs, primary care physicians, nurse practitioners, physician assistants, and through telehealth platforms.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Lo Zumandimine works primarily by suppressing ovulation. The hormones ethinyl estradiol and drospirenone act together to inhibit the hypothalamic-pituitary axis, preventing the release of LH (luteinizing hormone) and FSH (follicle-stimulating hormone) that would otherwise trigger the release of an egg. Clinical studies demonstrated more than 90% ovulation inhibition with this combination.
Two secondary mechanisms provide additional protection: thickening of cervical mucus (making it harder for sperm to reach an egg) and thinning of the uterine lining (reducing the chance of implantation if fertilization occurs). Drospirenone is unique among progestins in that it is a spironolactone analogue with both anti-mineralocorticoid activity (reducing water retention and bloating) and antiandrogenic activity (blocking androgen receptors that contribute to acne and excess oil production).
The 24/4 regimen (24 active + 4 inert days) minimizes the hormone-free interval compared to traditional 21/7 pills. This shorter break stabilizes hormonal levels throughout the month, which is the key mechanism behind Lo Zumandimine's effectiveness for PMDD — a condition driven by hormonal fluctuations in the premenstrual phase.
3 mg / 0.02 mg — tablet (28-day pack)
24 active tablets (drospirenone 3 mg / ethinyl estradiol 0.02 mg) + 4 inert tablets; 24/4 regimen
3 mg / 0.02 mg — kit (3-pack)
84-tablet supply (3 cycles); available for 90-day fills
As of 2026, Lo Zumandimine 28 Day is not on the FDA's official Drug Shortage Database. Aurobindo Pharma continues to manufacture and distribute the product. However, some patients encounter pharmacy-level stock gaps due to distributor allocation practices and generic brand fragmentation across the drospirenone/EE market.
Several drospirenone/EE generics have been discontinued (notably Vestura by Teva, and certain Barr Laboratories NDCs as of mid-2025), which has narrowed the generic landscape. Pharmacies now primarily stock Lo Zumandimine, Loryna, Nikki, Gianvi, and Syeda — but not all pharmacies carry all brands. The findability score of 80/100 reflects that the medication is generally available nationally, but some patients may need to search across a few pharmacies to find their specific brand.
If you're having trouble finding Lo Zumandimine at your local pharmacy, medfinder can call pharmacies in your area on your behalf to find which ones have your prescription in stock, then text you the results.
Lo Zumandimine is not a controlled substance and is not subject to any REMS program. There are no special DEA registration requirements or prescriber certification requirements. Any licensed prescriber in the United States can prescribe it, including through telehealth in all 50 states.
Telehealth platforms including Nurx, Pandia Health, Amazon Clinic, and Hims/Hers can prescribe Lo Zumandimine via online consultation and ship the medication directly to patients, available in all 50 states without an in-person visit.
No. Lo Zumandimine 28 Day is not a controlled substance and is not scheduled by the DEA. It does not require any special prescriber registration, DEA authorization, or REMS (Risk Evaluation and Mitigation Strategy) program.
Any licensed prescriber — including physicians (MD/DO), nurse practitioners (NP), certified nurse-midwives (CNM), and physician assistants (PA) — can prescribe Lo Zumandimine without any additional certification. Prescriptions can be sent electronically, phoned in, or faxed like any other non-controlled medication. Refills can be authorized for up to 12 months without an in-person visit in most states. Telehealth platforms can also prescribe Lo Zumandimine in all 50 states, making access straightforward.
Most common side effects are mild and often improve after 2-3 cycles:
Know what you need? Skip the search.
Loryna (28 Day)
AB-rated generic of Yaz; identical active ingredients (DRSP 3mg/EE 0.02mg); 24/4 regimen; widely available
Nikki (28 Day)
AB-rated Yaz generic; inactive ingredients considered most similar to brand Yaz; 24/4 regimen
Gianvi (28 Day)
AB-rated Yaz generic by Teva; same active ingredients; widely stocked at major chains
Syeda (28 Day)
AB-rated Yaz equivalent; available at most national pharmacy chains
Sprintec / Tri-Sprintec
Norgestimate/ethinyl estradiol COC; different progestin; widely available and inexpensive; no PMDD or acne indication
Prefer Lo Zumandimine 28 Day? We can find it.
Rifampin
majorStrong CYP3A4 inducer; significantly reduces Lo Zumandimine contraceptive effectiveness. Use backup contraception during and for 28 days after rifampin course.
Carbamazepine (Tegretol)
majorCYP3A4 inducer; reduces hormone levels and contraceptive effectiveness. May require higher-dose COC or alternative contraceptive.
Phenytoin (Dilantin)
majorCYP3A4 inducer; reduces contraceptive hormone levels. Use backup contraception.
St. John's Wort
majorHerbal CYP3A4 inducer; reduces contraceptive effectiveness and may cause breakthrough bleeding. Avoid concurrent use.
Lamotrigine (Lamictal)
majorCOCs with EE significantly reduce lamotrigine plasma levels via glucuronidation induction, potentially reducing seizure control. Dose adjustment may be needed.
Ombitasvir/paritaprevir/ritonavir (Viekira Pak)
majorContraindicated. Causes significant ALT elevations when combined with EE/drospirenone.
Spironolactone (Aldactone)
moderateAdditive hyperkalemia risk due to drospirenone's anti-mineralocorticoid activity. Monitor serum potassium.
ACE inhibitors (lisinopril, enalapril)
moderateIncreased hyperkalemia risk when combined with drospirenone. Potassium monitoring recommended.
Angiotensin II receptor blockers (losartan, valsartan)
moderateIncreased hyperkalemia risk. Monitor potassium in first treatment cycle.
NSAIDs (long-term use)
minorTheoretical additive hyperkalemia risk with drospirenone. Occasional use generally acceptable; long-term use warrants monitoring.
Lo Zumandimine 28 Day is a well-established, widely used generic oral contraceptive with a multi-indication profile that sets it apart from many competitors. Its drospirenone/ethinyl estradiol 0.02 mg combination — the same as Yaz — provides contraception, PMDD symptom management, and moderate acne treatment in one daily pill. The 24/4 regimen minimizes hormonal fluctuations, making it a preferred choice for women who struggle with hormone-related mood and physical symptoms.
While Lo Zumandimine is not in an official FDA shortage, pharmacy-level availability can be inconsistent, particularly as some other drospirenone/EE generics have been discontinued. Patients who encounter stock issues can usually find an AB-rated equivalent (Loryna, Nikki, Gianvi, or Syeda) at their pharmacy or a neighboring one. Asking your prescriber to write the prescription using the generic ingredient name with substitution permitted is one of the most effective ways to avoid refill delays.
If you're struggling to locate Lo Zumandimine or an equivalent near you, medfinder calls pharmacies in your area on your behalf to identify which ones have your prescription in stock and texts you the results — saving you from the frustrating experience of calling pharmacies one by one.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards